Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986613000060/alxn10k12312012.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
Alexion Pharmaceuticals, Inc. Irving Adler Executive Director, Corporate Communications (203) 271-8210 | Alexion Pharmaceuticals, Inc. Kim Diamond (Media) Director, Corporate Communications (203) 439-9600 | Rx Communications (Investors) Rhonda Chiger (917) 322-2569 |
• | Q4 2012 net product sales increased 41 percent to $320.5 million, compared to $227.6 million in Q4 2011. |
• | Q4 2012 GAAP net income increased 68 percent to $81.0 million, or $0.40 per share, compared to Q4 2011 GAAP net income of $48.2 million, or $0.25 per share. |
• | Q4 2012 non-GAAP net income increased 52 percent to $122.3 million, or $0.60 per share, compared to Q4 2011 non-GAAP net income of $80.5 million, or $0.41 per share. |
• | 2012 net product sales increased 45 percent to $1.134 billion, compared to $783.4 million in 2011. |
• | 2012 GAAP net income increased 45 percent to $254.8 million, or $1.28 per share, compared to 2011 GAAP net income of $175.3 million, or $0.91 per share. |
• | 2012 non-GAAP net income increased 60 percent to $425.2 million, or $2.13 per share, compared to 2011 non-GAAP net income of $266.1 million, or $1.38 per share. |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986613000060/alxn10k12312012.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-13-000060
Submitted to the SEC: Tue Feb 19 2013 10:05:39 AM EST
Accepted by the SEC: Tue Feb 19 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations